2
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
23
Liver Neoplasms
4
Recurrence
2
Carcinoma, Non-Small-Cell Lung
2
Uveal Melanoma
1
Sarcoma
1
Recurrence Hepatocellular Carcinoma
1
Pleural Neoplasms
1
Pancreatic Adenocarcinoma
1
Neuroendocrine Tumors
1
Neoplastic Cells, Circulating
1
Neoplasm Recurrence, Local
1
Mediastinal Neoplasms
1
Malignant Neoplasm in the Head and Neck
1
Lung Neoplasms
1
Lung Metastases
1
Liver Cirrhosis
1
Hypoxia
1
HCC
1
Colorectal Cancer Metastatic
1
Colonic Neoplasms
1
Interventions
Bevacizumab
19
Capecitabine
15
Oxaliplatin
11
Irinotecan
11
Cetuximab
11
Fluorouracil
10
Leucovorin
8
aflibercept
7
Panitumumab
6
trifluridine tipiracil drug combination
4
Nivolumab
4
sintilimab
3
regorafenib
3
Ipilimumab
3
Vemurafenib
2
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
2
Folfox protocol
2
Drug Therapy
2
tremelimumab
1
spartalizumab
1
raltitrexed
1
pembrolizumab
1
monoclonal antibody YYB-101
1
masitinib
1
irinotecan sucrosofate
1
glucopyranosyl lipid-A
1
folfirinox
1
durvalumab
1
camrelizumab
1
balstilimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Colorectal Cancer Metastatic
×
Ethiodized Oil
×
Clear all
NCT01959061
2017-03-13
TACE
Nanjing Chia-tai Tianqing Pharmaceutical
Phase 4
Unknown
320 enrolled